Zeng Huihui, Cai Haodong, Wang Ying, Shen Ying
Department of Pediatrics, Beijing Ditan Hospital affiliated with Capital Medical University, Beijing, China.
Department of Hepatology, Beijing Ditan Hospital affiliated with Capital Medical University, Beijing, China.
Int J Infect Dis. 2015 Apr;33:97-103. doi: 10.1016/j.ijid.2014.09.002. Epub 2014 Oct 24.
We studied the growth and development of children prenatally exposed to telbivudine used to treat chronic hepatitis B virus (HBV) infection in their mothers.
Maternal abnormalities during pregnancy and delivery and infant congenital anomalies, physical development status, developmental quotient (DQ), HBV vertical transmission status, and HBV vaccination outcomes of 54 infants were evaluated (2010-2013).
No fetal abnormalities were observed during pregnancy or delivery. Postpartum, three infants (5.56%) had abnormalities: ankyloglossia, cutaneous hemangioma, and vaginal canal leak. Height and weight were within the normal range at birth and at 6 weeks, but were higher than the reference at 12 months (p<0.05). Body mass index increased gradually with age (p<0.05). DQ scores were normal (84.81%, 229/270) in 37 children (68.52%), abnormal or suspicious for a developmental delay (15.19%, 41/270) in 17 children (31.48%), and indicated a developmental delay (4.07%, 11/270) in seven children (12.96%). There were no significant differences in developmental delay between children prenatally exposed to telbivudine and controls (p>0.05). HBV vertical transmission was successfully blocked in all infants. The effective HBV vaccination rate was 98.15% (53/54).
The growth and development of children prenatally exposed to telbivudine was normal, indicating that telbivudine treatment during pregnancy is safe and effective.
我们研究了母亲孕期使用替比夫定治疗慢性乙型肝炎病毒（HBV）感染的儿童的生长发育情况。
评估了54例婴儿（2010 - 2013年）孕期和分娩时母亲的异常情况、婴儿先天性异常、身体发育状况、发育商（DQ）、HBV垂直传播状况以及HBV疫苗接种结果。
孕期或分娩时未观察到胎儿异常。产后，3例婴儿（5.56%）出现异常：舌系带过短、皮肤血管瘤和阴道管瘘。出生时及6周时身高和体重在正常范围内，但12个月时高于参考值（p<0.05）。体重指数随年龄逐渐增加（p<0.05）。37名儿童（68.52%）的DQ评分正常（229/270），17名儿童（31.48%）异常或疑似发育迟缓（41/270），7名儿童（12.96%）显示发育迟缓（11/270）。产前暴露于替比夫定的儿童与对照组在发育迟缓方面无显著差异（p>0.05）。所有婴儿的HBV垂直传播均成功阻断。HBV疫苗有效接种率为98.15%（53/54）。
产前暴露于替比夫定的儿童生长发育正常，表明孕期使用替比夫定治疗安全有效。
